Tonix Pharmaceuticals

July 27, 2016July 27, 2016

2nd Phase 3 Study of Low-dose Oral Treatment for Fibromyalgia Gets Underway

News

Tonix Pharmaceuticals announced that the first patient has been dosed in RE-AFFIRM, the company’s second Phase 3 clinical trial evaluating its cyclobenzaprine HCl sublingual tablets, known as TNX-102 SL, as a low-dose nighttime treatment for fibromyalgia. TNX-102 SL ... Read more

June 8, 2016June 8, 2016

2016 BIO International: Tonix Updates on Fibromyalgia, PTSD Medicine

News

Tonix Pharmaceuticals Holding Corp, focused on developing next-generation medicines for central nervous system disorders that include fibromyalgia and post-traumatic stress disorder (PTSD), presented reports at the recent 2016 BIO International Convention in San Francisco, ... Read more

May 4, 2016May 19, 2016

Tonix Pharmaceuticals Completes Enrollment in Fibromyalgia Phase 3 Clinical Trial

News

Tonix Pharmaceuticals, a company developing next-gen therapies for disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), has completed enrollment in its Phase 3 AFFIRM clinical trial of TNX-102 ... Read more

March 30, 2016May 19, 2016

Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference

News

Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the ... Read more

August 11, 2015August 11, 2015

Tonix Pharmaceuticals Clinical Trials Underway Investigating New Drugs For Fibromyalgia, PTSD, and Tension Headache

News

Clinical-stage pharmaceutical company Tonix Pharmaceuticals Holding Corp. in conjunction with announcing its second quarter 2015 financial results, reports progress in developing next-generation medicines for treating fibromyalgia, post-traumatic stress disorder (PTSD), ... Read more

June 24, 2015June 24, 2015

Novel Drug Improves Sleep And Pain Scores In Fibromyalgia Patients

News

During the European League Against Rheumatism Annual European Congress of Rheumatology held in Rome, researchers presented data showing sublingual TNX-102 SL improved sleep quality and other fibromyalgia symptoms. The study ... Read more

May 27, 2015May 27, 2015

Tonix Pharmaceuticals Announces Acceptance of Two Fibromyalgia-Related Abstracts for Presentation at EULAR

News

Tonix Pharmaceuticals Holding Corp, a clinical-stage firm currently advancing next-generation medicines to address the unmet needs related to post-traumatic stress disorder, fibromyalgia, and episodic tension-type headache, recently announced that two of the company’s abstracts were accepted and ... Read more

January 16, 2015January 16, 2015

Tonix Pharmaceuticals Will Present At The Noble Financial Annual Investor Conference

News

Tonix Pharmaceuticals Holding Corp will be presenting at the Eleventh Annual Noble Financial Capital Markets Investor Conference that will take place in Sandpiper Bay, FL. The company’s CEO and president, Seth Lederman, will be ... Read more

January 8, 2015January 8, 2015

Tonix Pharmaceuticals Receives FDA Guidance To Continue Development of Therapy For Fibromyalgia

News

The Tonix Pharmaceuticals Holding Corp. received written guidance from the United States Food and Drug Administration (FDA) on the company’s Phase 3 clinical trials for the TNX-102 SL in fibromyalgia. Seth Lederman, ... Read more